Press release
Gastric Neuroendocrine Tumors Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Ipsen, Taproot Health, Camurus AB, Novartis
DelveInsight's "Gastric Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Gastric Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Gastric Neuroendocrine Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Gastric Neuroendocrine Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastric Neuroendocrine Tumors Market Forecast [https://www.delveinsight.com/sample-request/gastric-neuroendocrine-tumors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Gastric Neuroendocrine Tumors Market Report
* The Gastric Neuroendocrine Tumors market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
* G-NETs are rare gastric tumors, and the diagnosis is usually accidental. Hence, they are often diagnosed in later stages. However, the number of diagnosed NETs has been increasing for years
* According to the American Society of Clinical Oncology (ASCO), out of all gastrointestinal NETs, 2-4% are found in the stomach
* Type I and Type III account for 70-80% and 15-20% of the total cases of G-NET, respectively. Type II is very rare, and recently Type IV is identified in some studies
* According to a review article by Ahmed et al. (2020), NETs constitute only 0.5% of all malignant conditions and 2% of all malignant tumors of the Gastrointestinal
* Solucin (n.c.a. 177Lu-Edotreotide/n.c.a. 177Lu-DOTATOC), RRx-001 and Abemaciclib are the most anticipated emerging products for the Gastric Neuroendocrine Tumors treatment, that are in the mid or late phase of clinical trials awaiting approval
* Key Gastric Neuroendocrine Tumors Companies: Ipsen, Taproot Health, Camurus AB, Novartis Pharmaceuticals, and others
* Key Gastric Neuroendocrine Tumors Therapies: Ribociclib, CAM2029, Lutathera, Octreotide LAR, Satoreotide trizoxetan, and others
* The Gastric Neuroendocrine Tumors epidemiology based on gender analyzed that around 60% of the cases of G-NET found in the SEER database were females
Request a sample for the Gastric Neuroendocrine Tumors Market Report:
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market [https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Gastric Neuroendocrine Tumors Overview
According to the Neuroendocrine Tumor Patient Foundation (n.d.)- "Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into tumor".
Gastric Neuroendocrine Tumors Epidemiology Segmentation:
The Gastric Neuroendocrine Tumors market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
* Total Prevalence of Gastric Neuroendocrine Tumors
* Prevalent Cases of Gastric Neuroendocrine Tumors by severity
* Gender-specific Prevalence of Gastric Neuroendocrine Tumors
* Diagnosed Cases of Episodic and Chronic Gastric Neuroendocrine Tumors
Download the report to understand which factors are driving Gastric Neuroendocrine Tumors epidemiology trends @ Gastric Neuroendocrine Tumors Epidemiological Insights [https://www.delveinsight.com/sample-request/gastric-neuroendocrine-tumors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Gastric Neuroendocrine Tumors Market
The dynamics of the Gastric Neuroendocrine Tumors market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as CAM2029, Lutathera, and others during the forecasted period 2019-2032.
Gastric Neuroendocrine Tumors Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastric Neuroendocrine Tumors market or expected to get launched during the study period. The analysis covers Gastric Neuroendocrine Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Gastric Neuroendocrine Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Gastric Neuroendocrine Tumors Therapies
* Ribociclib
* CAM2029
* Lutathera
* Octreotide LAR
* Satoreotide trizoxetan
Gastric Neuroendocrine Tumors Key Companies
* Ipsen
* Taproot Health
* Camurus AB
* Novartis Pharmaceuticals
To know more about Gastric Neuroendocrine Tumors treatment, visit @ Gastric Neuroendocrine Tumors Medications [https://www.delveinsight.com/sample-request/gastric-neuroendocrine-tumors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Scope of the Gastric Neuroendocrine Tumors Market Report
* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Gastric Neuroendocrine Tumors Companies: Ipsen, Taproot Health, Camurus AB, Novartis Pharmaceuticals, and others
* Key Gastric Neuroendocrine Tumors Therapies: Ribociclib, CAM2029, Lutathera, Octreotide LAR, Satoreotide trizoxetan, and others
* Therapeutic Assessment: Gastric Neuroendocrine Tumors current marketed and Gastric Neuroendocrine Tumors emerging therapies
* Gastric Neuroendocrine Tumors Market Dynamics: Gastric Neuroendocrine Tumors market drivers and barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Gastric Neuroendocrine Tumors Unmet Needs, KOL's views, Analyst's views, Gastric Neuroendocrine Tumors Market Access and Reimbursement
Discover more about therapies set to grab major Gastric Neuroendocrine Tumors market share @ Gastric Neuroendocrine Tumors market forecast [https://www.delveinsight.com/sample-request/gastric-neuroendocrine-tumors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Gastric Neuroendocrine Tumors Market Report Introduction
2. Executive Summary for Gastric Neuroendocrine Tumors
3. SWOT analysis of Gastric Neuroendocrine Tumors
4. Gastric Neuroendocrine Tumors Patient Share (%) Overview at a Glance
5. Gastric Neuroendocrine Tumors Market Overview at a Glance
6. Gastric Neuroendocrine Tumors Disease Background and Overview
7. Gastric Neuroendocrine Tumors Epidemiology and Patient Population
8. Country-Specific Patient Population of Gastric Neuroendocrine Tumors
9. Gastric Neuroendocrine Tumors Current Treatment and Medical Practices
10. Gastric Neuroendocrine Tumors Unmet Needs
11. Gastric Neuroendocrine Tumors Emerging Therapies
12. Gastric Neuroendocrine Tumors Market Outlook
13. Country-Wise Gastric Neuroendocrine Tumors Market Analysis (2019-2032)
14. Gastric Neuroendocrine Tumors Market Access and Reimbursement of Therapies
15. Gastric Neuroendocrine Tumors Market drivers
16. Gastric Neuroendocrine Tumors Market barriers
17. Gastric Neuroendocrine Tumors Appendix
18. Gastric Neuroendocrine Tumors Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gastric-neuroendocrine-tumors-market-and-epidemiology-forecast-2032-population-data-drugs-companies-and-competitive-intelligence-by-delveinsight-ipsen-taproot-health-camurus-ab-novartis]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gastric Neuroendocrine Tumors Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Ipsen, Taproot Health, Camurus AB, Novartis here
News-ID: 3462309 • Views: …
More Releases from ABNewswire
98% Consistency, 0 Staff: Anno Robot Redefines Airport Coffee in 60 Countries
As millions of travellers rush through terminals worldwide, one constant complaint has finally been solved: bad airport coffee served slowly by exhausted staff. Shenzhen-based Anno Robot [https://www.coffeerobotsanno.com/] has quietly eliminated both problems with fully robotic kiosks that deliver 98% brew-to-brew consistency and require zero human baristas. By November 2025, these AI-powered stations are operating in airports and high-traffic hubs across more than 60 countries, marking a turning point for the…
FAXVIN Unveils Enhanced CarRank, a 0-100 Single-Score Summary That Makes Used-Ca …
Updated methodology brings additional partner data and refined signal weighting so shoppers and dealers can rank and compare vehicles in seconds.
WALNUT, Calif. - Nov. 19, 2025 - FAXVIN today announced a significant update to CarRank, its 0-100 vehicle-history metric designed to help shoppers and dealers compare used cars at a glance. The latest release incorporates additional data sources and methodology refinements that improve how risk signals are weighted across title…
Global Pro AV Market Surges Toward USD 127.31 Billion by 2030, Led by Sony, Sams …
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025-2030.
According to Arizton research, the global pro AV market [https://www.arizton.com/market-reports/pro-av-market] was valued at USD 90.00 billion in 2024 and is projected to reach USD 127.31 billion by 2030, growing at a CAGR of 5.95% during the forecast period.
Explore the Full Market Insights: https://www.arizton.com/market-reports/pro-av-market
Report Summary:
Market Size (2030): USD 127.31 Billion
Market Size (2024): USD 90.00 Billion
CAGR (2024-2030): 5.95%
Historic…
Redway Power Launches High-Capacity 51.2V 420Ah Lithium Forklift Battery for Nex …
Redway Power, a leading OEM lithium battery manufacturer, proudly announces the launch of its latest innovation: the 51.2V 420Ah Lithium Forklift Battery [https://www.redwaypower.com/product/48v-420ah-forklift-lithium-battery/]. Designed for modern industrial operations, this next-generation battery combines high capacity, advanced safety features, and customizable OEM/ODM solutions to revolutionize warehouse productivity and material handling efficiency.
Introducing Next-Generation Power for Forklifts
The new 51.2V 420Ah battery is engineered to deliver exceptional energy efficiency and durability. With a nominal energy…
More Releases for Neuroendocrine
Neuroendocrine Carcinoma Market Massive Growth opportunity Ahead
Introduction
Neuroendocrine carcinoma (NEC) is a rare and aggressive form of cancer that arises from neuroendocrine cells, which are found throughout the body and are responsible for producing hormones. These tumors can occur in various organs, including the lungs, pancreas, liver, and gastrointestinal tract. Due to its often vague and non-specific symptoms, neuroendocrine carcinoma is frequently diagnosed at an advanced stage, making it challenging to treat effectively.
In recent years, however, there…
Rising Neuroendocrine Tumors Fuel Treatment Market Growth Driving Market Acceler …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Neuroendocrine Tumor Treatment Market Size By 2025?
The industry for treating neuroendocrine tumors has witnessed substantial growth in the previous years. The market size is projected to escalate from $2.17 billion in 2024 to $2.4 billion in 2025, with a compound annual growth rate (CAGR)…
Emerging Trends Influencing The Growth Of The Neuroendocrine Tumor Treatment Mar …
The Neuroendocrine Tumor Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Neuroendocrine Tumor Treatment Market Size Expected to Be by 2034?
The market for neuroendocrine tumor treatment has seen a significant expansion in recent years. Projected to grow from a value…
Prominent Neuroendocrine Tumor Treatment Market Trend for 2025: Clinical Trials …
How Are the key drivers contributing to the expansion of the neuroendocrine tumor treatment market?
The neuroendocrine tumor treatment market is forecasted to expand due to the increasing incidence of neuroendocrine tumors. Neuroendocrine tumors, or NETs, are rare growths that begin in neuroendocrine cells, and their treatment is vital to managing the symptoms, controlling the tumor's growth, and applying radiation therapy to destroy the cancerous cells. The American Society of Clinical…
Neuroendocrine Tumor Treatment Market – Forecast to 2026
According to a new market research report published by Global Market Estimates, the Global Neuroendocrine Tumor Treatment Market is projected to grow from USD 1.8 billion in 2021 to USD 2.1 billion by 2026 at a CAGR value of 5.7% between 2021 to 2026. High prevalence of neuropsychiatric malignancy, awareness regarding early cancer diagnosis, and an increasing number of government initiatives, the neuroendocrine tumor therapy market is expected to rise…
Neuroendocrine Cancer Market: Rising Prevalence of Neuroendocrine Cancer and Gro …
The market report titled ‘Global Neuroendocrine Cancer Market - Size, Share and Forecast (2019 - 2026)’ produced by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities.
Neuroendocrine Cancer Market Segmentation Analysis
Total Neuroendocrine Cancer Studies: 2499
By Drug Type
Everolimus
Sunitinib Malate
Lanreotide
Octreotide
Others
Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for the treatment of…
